SEC Form 4 · accession 0001209191-17-031377
Ovid Therapeutics Inc. · OVID
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yaron Werber
Officer — CBO, CFO, Sec. and Treas.
Period of report
May 10, 2017
Accepted (ET)
May 10, 2017 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636651
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $8.50 | May 10, 2017 | A | 93,022 | A | May 10, 2017 | Jan 19, 2027 | Common Stock | 93,022 | 93,022 | D |
Explanation of responses
- F1100% of the shares subject to the Stock Option vested and became exercisable upon the closing of the initial public offering resulting in gross proceeds to the Issuer of $75,000,000 in accordance with its terms.